CEO Dror Bashan highlighted the company’s focus on advancing its clinical pipeline, particularly PRX-115, its gout treatment candidate. The Phase 2 clinical trial for PRX-115 is planned for initiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results